JLP Health GmbH, founded by Prof. Josef Penninger and colleagues, employs cutting edge functional genomic technologies that enable the development of rational drugs to combat viral infections and other diseases with high unmet medical need, such as cancer and other life-threatening diseases. JLP's R&D activities are based in Vienna and supported by its subsidiary Acus in Cologne. The Joint Venture Angal Biotechnology enables the international scale-up and opens the Chinese market.
R&D:JLP Health develops novel medicines for unmet medical needs with focus on cancer research and viral infections. Through our unique forward genetic screening platform, we provide high-resolution information on molecular drug targets, uncover hidden efficacies and predict potential resistance mechanisms of candidate compounds. This information will be validated with unmatched reliability for innovative drug development projects.
Production:na
Services:Through our unique forward genetic screening platform, we provide high-resolution information on molecular drug targets, uncover hidden efficacies and predict potential resistance mechanisms of candidate compounds. This information will be validated with unmatched reliability for innovative drug development projects.
Sales/Distribution:na
Himmelhofgasse 62
1130/Wien
Vienna
Contact:
Telephone: 6649253172
Email: sandra.prassel@jlphealth.com
Website